A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

Drug Design, Development and Therapy, 05/08/2012

The efficacy and safety of pasireotide is currently being evaluated in patients with acromegaly, Cushing's disease, NET, and various non–neuroendocrine disorders.

Print Article Summary Cat 2 CME Report